09.01.20

Oculis Establishes Presence in US and Appoints Sylvia Cheung as Chief Financial Officer

Source: Oculis

Oculis established a US entity, Oculis Inc., and announced the appointment of Sylvia Cheung as Chief Financial Officer (CFO). Ms. Cheung will be based in the newly established Oculis US entity and succeeds Páll Ragnar Jóhannesson who becomes Oculis Chief Strategy Officer.

“We are very pleased to be proceeding with our U.S. expansion and I am thrilled to welcome Sylvia as our new CFO who will play a key role in the next phase of our corporate journey. She is an accomplished executive with a proven track record of financial and operational leadership in the life sciences industry. Her experience in building and financing biotechnology and medical device companies, together with her knowledge of U.S. financial and public capital markets made her a natural choice to fill this key role,” Riad Sherif, MD, CEO of Oculis, said in a company news release. “Oculis is now preparing for its next important strategic steps and we look forward to leveraging Sylvia’s significant experience and expertise as we continue to progress towards our corporate goals.”

Dr. Sherif continued: “I would also like to thank Páll for his key contribution as CFO. I am confident that we would not be where we are today without his expertise and drive, I feel privileged to have him on the team and to continue working with him on key strategic initiatives for Oculis.”

Ms. Cheung has 20 years of financial and general management experience at emerging growth life science companies. She joins Oculis from the NASDAQ-listed company Anika Therapeutics, Inc. where she was CFO since 2013.

 “Oculis’ pipeline candidates have the potential to be game changers in the treatment of eye diseases. I am very pleased to be joining the company at such a pivotal and exciting time and look forward to working with the excellent team to ensure they have the financial resources needed to deliver on their goal of bringing novel products, such as OCS-01 and OCS-02, that can improve the sight and lives of patients, to market,” Ms. Cheung said.

Related Content